文献速递慢阻肺肺栓塞与肺血管病

内脏脂肪代谢评分与慢阻肺不良结局的关联

Association between metabolic score for visceral fat and adverse outcomes in chronic obstructive pulmonary disease
RSS 订阅 · BMJ Open Respiratory Research

基于英国生物银行7246例及美国NHANES 869例慢阻肺患者,分析内脏脂肪代谢评分(METS-VF)与死亡及心肺结局的关联。最高四分位METS-VF与全因死亡、心血管死亡、慢阻肺特异性死亡、肺心病、肺栓塞和心衰风险显著升高相关,NHANES外部验证结果一致。METS-VF或可作为慢阻肺风险分层的实用预后生物标志物。

要点

  • METS-VF最高四分位者全因死亡风险显著升高(HR 1.467),心血管死亡风险更高(HR 3.000)。
  • METS-VF与肺心病(HR 3.505)、心衰(HR 2.567)、肺栓塞(HR 2.301)风险独立相关。
  • CRP和白细胞计数部分介导METS-VF与死亡及心肺结局的关联,血小板无显著中介效应。

核心结论

  • METS-VF升高与慢阻肺患者长期死亡及心肺并发症风险增加一致相关,在两个独立队列中均得到验证。
  • METS-VF可能作为慢阻肺临床管理中风险分层的实用预后生物标志物。

研究设计与样本

  • 分析英国生物银行7246例慢阻肺患者及美国NHANES 1999–2018年869例慢阻肺患者,METS-VF按四分位分组。
  • 英国生物银行采用Cox模型、限制性立方样条、Kaplan-Meier曲线、时间依赖ROC及中介分析;NHANES作为外部验证队列采用调查加权Cox模型等。

主要发现

  • 英国生物银行中,限制性立方样条显示METS-VF与全因死亡和心血管死亡呈非线性关联,共同拐点为7.03,与次要结局呈线性关联。
  • 最高METS-VF四分位与全因死亡(HR 1.467)、心血管死亡(HR 3.000)、慢阻肺特异性死亡(HR 1.952)、肺心病(HR 3.505)、肺栓塞(HR 2.301)和心衰(HR 2.567)风险显著升高相关。
  • NHANES中最高METS-VF四分位仍与全因死亡(HR 3.337)和心血管死亡(HR 3.011)显著相关。
  • 时间依赖ROC分析显示两个队列随访期间区分度中等但稳定。
  • 中介分析显示CRP和白细胞计数部分介导METS-VF与死亡及心肺结局的关联,血小板无显著中介效应。

关键数值与推荐

  • 英国生物银行中METS-VF与全因死亡和心血管死亡的非线性关联拐点为7.03。
  • 最高四分位METS-VF的HR值:全因死亡1.467、心血管死亡3.000、慢阻肺特异性死亡1.952、肺心病3.505、肺栓塞2.301、心衰2.567。
  • NHANES中最高四分位METS-VF的HR值:全因死亡3.337、心血管死亡3.011。

临床怎么用

  • 可将METS-VF作为慢阻肺患者风险分层的参考指标,识别死亡及心肺并发症高风险人群。
  • 对METS-VF升高者,可关注CRP和白细胞计数等炎症指标,其部分介导了不良结局关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background The metabolic score of visceral fat (METS-VF) is linked to chronic obstructive pulmonary disease (COPD) incidence, while its association with mortality and adverse outcomes in patients with COPD remains unclear. Materials and methods We analysed 7246 participants with COPD from the UK Biobank and 869 from US National Health and Nutrition Examination Survey (US NHANES) (1999–2018). METS-VF was categorised into quartiles. In UK Biobank, outcomes included all-cause, cardiovascular disease (CVD), COPD-specific mortality, pulmonary heart disease (PHD), pulmonary embolism (PE) and heart failure (HF); in NHANES, only all-cause and CVD mortality were evaluated. UK Biobank analyses used Cox models, restricted cubic splines, Kaplan-Meier curves, time-dependent receiver operating characteristic (ROC) curves and mediation analysis (C reactive protein (CRP), white blood cell count (WBC), platelet count (PLT)). NHANES served as an external validation cohort using survey-weighted Cox models, subgroup and sensitivity analyses and time-dependent ROC for the two mortality outcomes. Results In UK Biobank, restricted cubic splines identified non-linear associations of METS-VF with all-cause and CVD mortality, with a common inflection point at 7.03, and linear associations with secondary outcomes. Compared with the lowest quartile, the highest METS-VF quartile showed significantly higher risks of all-cause mortality (HR 1.467), CVD mortality (HR 3.000), COPD-specific mortality (HR 1.952), PHD (HR 3.505), PE (HR 2.301) and HF (HR 2.567). Similar positive associations were observed in NHANES, where the highest METS-VF quartile remained significantly associated with all-cause mortality (HR 3.337) and CVD mortality (HR 3.011). Time-dependent ROC analyses demonstrated modest but stable discrimination across follow-up in both cohorts. Mediation analyses showed that CRP and WBC partially mediated the associations of METS-VF with mortality and cardiopulmonary outcomes, whereas PLT did not exhibit significant mediation effects. Conclusions Elevated METS-VF is consistently associated with increased long-term risks of mortality and cardiopulmonary complications in COPD across independent discovery and validation cohorts. METS-VF may serve as a practical prognostic biomarker for risk stratification in the clinical management of COPD.

来源:BMJ Open Respiratory Research,查看原文。版权归原作者所有。

引用

  1. BMJ Open Respiratory Research:Association between metabolic score for visceral fat and adverse outcomes in chronic obstructive pulmonary disease

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。